D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS), a $975 million market cap biotechnology company currently trading at $17.90, will present multiple abstracts on its oral bradykinin B2 receptor antagonist deucrictibant at the US Hereditary Angioedema Association’s 2025 National Summit, scheduled for July 10-13 in Baltimore. According to InvestingPro data, four analysts have recently revised their earnings estimates upward for the upcoming period.
The presentations will showcase data from several clinical trials evaluating deucrictibant for both prevention and treatment of hereditary angioedema (HAE) attacks. The company will present findings from the CHAPTER-1 open-label extension study on long-term safety, efficacy, disease control, and quality of life improvements with prophylactic use of deucrictibant. With a strong financial health score of FAIR from InvestingPro, the company maintains robust liquidity with a current ratio of 11.1, though investors should note its significant ongoing R&D investments.
Additional presentations will cover results from the RAPIDe-2 extension study on long-term safety and efficacy for treating HAE attacks, durability of response to single-dose treatment, and a propensity score-matched analysis comparing deucrictibant to standard of care.
The company will also present the design of its ongoing CHAPTER-3 Phase 3 trial, which is evaluating deucrictibant extended-release tablets for HAE attack prevention.
All six poster presentations are scheduled for Friday, July 11, from 12:30-13:30 ET at the summit. Presenters include several physicians specializing in HAE research, including Dr. Michael E. Manning, Dr. H. Henry Li, Dr. Marc A. Riedl, Dr. Joshua S. Jacobs, and Dr. Mark D. Scarupa.
Pharvaris is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including HAE and acquired angioedema due to C1 inhibitor deficiency. The company currently has two pivotal Phase 3 studies underway: CHAPTER-3 for HAE prevention and RAPIDe-3 for on-demand treatment of HAE attacks.
The information is based on a press release statement from Pharvaris.
In other recent news, Pharvaris has presented promising data on its oral treatment, deucrictibant, at the European Academy of Allergy and Clinical Immunology Congress. The drug, aimed at treating hereditary angioedema (HAE), demonstrated effective symptom relief and attack reduction in ongoing studies, with a significant percentage of attacks resolving within 24 hours. Pharvaris is also expanding its research to include acquired angioedema, with a new Phase 3 trial planned for this year. In addition, the company received orphan drug designation from the European Commission for deucrictibant, highlighting its potential in treating bradykinin-mediated angioedema beyond HAE.
Analysts at Citizens JMP and JMP Securities have maintained their Market Outperform rating for Pharvaris, with a price target of $55, reflecting confidence in the company’s strategic developments and upcoming milestones. Pharvaris continues to advance its clinical trials, with pivotal data readouts expected in the next 18 months. The company is actively exploring new endpoints and biomarkers to enhance its treatment offerings. These developments underscore Pharvaris’s commitment to addressing unmet needs in angioedema treatment, with the potential for significant market impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.